Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab vs Cetuximab in KRAS Wild-type mCRC
NCT01001377Phase 3Completed
- Sponsor
- Amgen
- Start
- Feb 2010
- Primary completion
- Feb 2013
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 29
01
Overview
A Phase 3 trial of panitumumab in metastatic colorectal cancer (mCRC), sponsored by Amgen. Started Feb 2010; status: completed.
02
Drugs
panitumumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01001377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01001377.